Chimerix (CMRX) Scheduled to Post Quarterly Earnings on Thursday

Chimerix (NASDAQ:CMRX) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) EPS for the quarter, hitting analysts’ consensus estimates of ($0.23). The business had revenue of $0.13 million during the quarter, compared to the consensus estimate of $1.26 million. During the same quarter in the previous year, the firm posted ($0.21) earnings per share. On average, analysts expect Chimerix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Chimerix Stock Up 2.1 %

Shares of NASDAQ:CMRX opened at $0.99 on Friday. The business has a 50 day moving average price of $0.90 and a 200 day moving average price of $0.91. The company has a market cap of $88.74 million, a price-to-earnings ratio of -1.04 and a beta of 1.12. Chimerix has a twelve month low of $0.75 and a twelve month high of $1.30.

Analysts Set New Price Targets

CMRX has been the subject of a number of recent analyst reports. Wedbush reiterated an “outperform” rating and issued a $6.00 price objective on shares of Chimerix in a report on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Chimerix in a research report on Wednesday, August 14th. Finally, StockNews.com raised shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Wednesday, August 21st.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.